Nanobiotix S.A.(NBTX)Earnings, Financials & Key Ratios

NBTX•NASDAQ

$38.80

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryRadiopharmaceuticals and Targeted Radiation

AboutNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.Show more

Revenue$30M+512.3%
EBITDA-$9M+86.2%
Net Income-$24M+64.8%
EPS (Diluted)-0.50+65.3%
Gross Margin100%
EBITDA Margin-31.45%-103.3%
Operating Margin-36.49%-103.8%
Net Margin-80.83%-108.5%

NBTX Price & Volume

Nanobiotix S.A. (NBTX) stock price & volume — 10-year historical chart

Loading chart...

Erratic Milestone Revenue Masks Structural Cash Burn

Investment Thesis • Updated 2025Q4

VerdictNegative: The company exhibits a structural inability to achieve self-sustainability

Growth:Mixed

Profitability:Negative

Financial:Strained

Cash Flow:Burning

Primary Risk:Clinical trial funding runway

Key Thesis Takeaways

Nanobiotix remains a high-risk clinical-stage entity where revenue volatility, driven by lumpy milestone recognition, obscures the underlying lack of commercial scalability for the NBTXR3 platform.
The company's reliance on external capital is underscored by a deteriorating equity position of negative $84.5 million and a persistent inability to cover R&D expenses, which reached $8.6 million in 2025Q4.
Investors should monitor the company's ability to manage its $95.3 million debt load against the backdrop of ongoing clinical development requirements.

Verdict Logic

evidenced by a $16.4 million free cash flow deficit in 2025Q4 and a current ratio that has compressed to 1.09.

NBTX Growth Metrics

Nanobiotix S.A. (NBTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years22.13%

5 Years66.38%

3 Years83.77%

TTM-45.22%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM4.8%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM29.45%

Return on Capital

10 Years-104.22%

5 Years-124.68%

3 Years-152.44%

Last Year-115.48%

NBTX Recent Earnings

Nanobiotix S.A. (NBTX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (60%)●Beat Revenue 3/12 qtrs (33%)

Q2 2026Latest

Mar 31, 2026

Metric

Actual

Est

EPS

$0.46-250.7%

$0.30

Rev

$4M-93.2%

$52M

Q4 2025

Sep 30, 2025

Metric

Actual

Est

EPS

$0.13+45.9%

$0.25

Rev

$31M+31.2%

$24M

Q2 2025

Apr 2, 2025

Metric

Actual

Est

EPS

$1.01-63.5%

$0.62

Rev

$22M-709.2%

$4M

Q4 2024

Nov 12, 2024

Metric

Actual

Est

EPS

$0.50+2.5%

$0.51

Rev

$10M-3.5%

$10M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Mar 31, 2026	$0.46vs $0.30-250.7%	$4Mvs $52M-93.2%
Q4 2025	Sep 30, 2025	$0.13vs $0.25+45.9%	$31Mvs $24M+31.2%
Q2 2025	Apr 2, 2025	$1.01vs $0.62-63.5%	$22Mvs $4M-709.2%
Q4 2024	Nov 12, 2024	$0.50vs $0.51+2.5%	$10Mvs $10M-3.5%

Based on last 12 quarters of dataView full earnings history →

Latest NBTX News

Recent stock market news and headlines for Nanobiotix S.A. (NBTX)

Seeking Alpha·Jun 25, 2026

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX's lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900's platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal.

Peers Comparison

Key metrics vs top competitors for Nanobiotix S.A. (NBTX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
NBTXNanobiotix S.A.Current	$38.80	$1.96B	-67.91	512.28%	-80.83%	—	—
NVCRNovoCure Limited	$17.72	$2.02B	-14.52	8.28%	-25.66%	-50.82%	—
ARAYAccuray Incorporated	$0.25	$29.63M	-16.07	2.68%	-10.76%	-77.48%	—
SENSSenseonics Holdings, Inc.	$5.33	$222.76M	-3.21	56.89%	-214.16%	-130%	—
ONCOOnconetix, Inc.	$1.07	$672.52K	-0.23	-67.7%	-1319.55%	-105.46%	—
CELCCelcuity Inc.	$115.72	$5.64B	-30.61	—	—	-244.61%	—

Compare NBTX vs Peers

Nanobiotix S.A. (NBTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for NBTX.

Scale Benchmark

vs MRK

Larger-name benchmark to compare NBTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ARAY, SENS, ONCO

Get notified when NBTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

NBTX Frequently Asked Questions

Nanobiotix S.A. (NBTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Nanobiotix S.A.'s revenue?

Nanobiotix S.A. (NBTX) reported $22.5M in revenue for fiscal year 2025. This represents a 1551% increase from $1.4M in 2011.

How fast is Nanobiotix S.A. growing?

Nanobiotix S.A. (NBTX) grew revenue by 512.3% over the past year. This is strong growth.

Is NBTX profitable?

Nanobiotix S.A. (NBTX) reported a net loss of $92.1M for fiscal year 2025.

Dividend & Returns

What is Nanobiotix S.A.'s free cash flow?

Nanobiotix S.A. (NBTX) had negative free cash flow of $54.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in NBTX back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

Mar 31, 2026

$0.46vs $0.30-250.7%

$4Mvs $52M-93.2%

Q4 2025

Sep 30, 2025

$0.13vs $0.25+45.9%

$31Mvs $24M+31.2%

Q2 2025

Apr 2, 2025

$1.01vs $0.62-63.5%

$22Mvs $4M-709.2%

Q4 2024

Nov 12, 2024

$0.50vs $0.51+2.5%

$10Mvs $10M-3.5%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

NBTXNanobiotix S.A.Current

$38.80

$1.96B

-67.91

512.28%

-80.83%

—

NVCRNovoCure Limited

$17.72

$2.02B

-14.52

8.28%

-25.66%

-50.82%

—

ARAYAccuray Incorporated

$0.25

$29.63M

-16.07

2.68%

-10.76%

-77.48%

—

SENSSenseonics Holdings, Inc.

$5.33

$222.76M

-3.21

56.89%

-214.16%

-130%

—

ONCOOnconetix, Inc.

$1.07

$672.52K

-0.23

-67.7%

-1319.55%

-105.46%

—

CELCCelcuity Inc.

$115.72

$5.64B

-30.61

—

-244.61%

—